Tibet Weixinkang Medicine Co Ltd Total Assets
Tibet Weixinkang Medicine Co Ltd total assets. Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) holds total assets worth CN¥1.96 Billion CNY (≈ $287.49 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 603676 market cap for the company's overall valuation and market capitalisation.
Total Assets of Tibet Weixinkang Medicine Co Ltd (2013–2025)
Total assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. This chart illustrates how Tibet Weixinkang Medicine Co Ltd's total assets have evolved over time, based on quarterly financial data. See Tibet Weixinkang Medicine Co Ltd (603676) share price today for real-time trading data and today's change.
Tibet Weixinkang Medicine Co Ltd - Asset Composition Analysis
Tibet Weixinkang Medicine Co Ltd Total Assets Breakdown (December 2025)
Tibet Weixinkang Medicine Co Ltd total assets breakdown as of December 2025. Tibet Weixinkang Medicine Co Ltd's total assets of CN¥1.96 Billion consist of 69.0% current assets and 31.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.4% |
| Accounts Receivable | CN¥131.58 Million | 7.1% |
| Inventory | CN¥59.82 Million | 3.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥36.90 Million | 2.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Tibet Weixinkang Medicine Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Weixinkang Medicine Co Ltd's current assets represent 69.0% of total assets in 2025, an increase from 52.2% in 2013.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2025, down from 32.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 7.1% of total assets.
Tibet Weixinkang Medicine Co Ltd Competitors by Total Assets
Key competitors of Tibet Weixinkang Medicine Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs96.12 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
China | CN¥3.61 Billion |
Tibet Weixinkang Medicine Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.62 | 3.84 | 2.34 |
| Quick Ratio | 3.45 | 3.71 | 2.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.01 Billion | CN¥991.84 Million | CN¥569.93 Million |
Tibet Weixinkang Medicine Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tibet Weixinkang Medicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 0.7% |
| Total Assets | CN¥1.87 Billion |
| Market Capitalization | $524.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Weixinkang Medicine Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tibet Weixinkang Medicine Co Ltd's assets grew by 0.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tibet Weixinkang Medicine Co Ltd (2013–2025)
The table below shows the annual total assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.87 Billion ≈ $273.18 Million |
+0.71% |
| 2024-12-31 | CN¥1.85 Billion ≈ $271.25 Million |
+4.32% |
| 2023-12-31 | CN¥1.78 Billion ≈ $260.02 Million |
+6.74% |
| 2022-12-31 | CN¥1.66 Billion ≈ $243.60 Million |
+11.31% |
| 2021-12-31 | CN¥1.50 Billion ≈ $218.85 Million |
+9.96% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.02 Million |
+4.25% |
| 2019-12-31 | CN¥1.30 Billion ≈ $190.91 Million |
+5.64% |
| 2018-12-31 | CN¥1.23 Billion ≈ $180.72 Million |
+21.48% |
| 2017-12-31 | CN¥1.02 Billion ≈ $148.76 Million |
+84.05% |
| 2016-12-31 | CN¥552.36 Million ≈ $80.83 Million |
+8.57% |
| 2015-12-31 | CN¥508.75 Million ≈ $74.45 Million |
+40.01% |
| 2014-12-31 | CN¥363.37 Million ≈ $53.17 Million |
+17.48% |
| 2013-12-31 | CN¥309.30 Million ≈ $45.26 Million |
-- |
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium… Read more